Advances in Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease (GvHD)

Yi-Bin Chen, MD, provides insight on common symptoms of GvHD (graft-versus-host disease), and shares tools for risk assessment and staging of the disease.

An expert in hematology/oncology comments on the importance of early detection and intervention of steroid-refractory chronic GvHD and considers approaches to switching treatments.

An expert in hematology-oncology comments on the importance of early detection and intervention of steroid-refractory chronic GvHD [graft-versus-host disease] and considers approaches to switching treatments.

Yi-Bin Chen, MD, reviews the currently available FDA-approved therapies for the management of steroid-refractory chronic GvHD.

Dr Yi-Bin Chen discusses the indications of ibrutinib, ruxolitinib, and belumosudil in steroid-refractory chronic graft-vs-host disease and shares his approach to selecting the optimal therapy for patients.

An expert in hematology/oncology reviews study data and results from the phase 3 REACH3 trial for steroid-refractory chronic graft-vs-host disease.

Yi-Bin Chen, MD, evaluates the safety and efficacy of ruxolitinib for second-line treatment for steroid-refractory chronic GVHD and discusses clinical implications from the REACH3 trial.

Yi-Bin Chen, MD, shares insight on unmet needs and the future treatment landscape for patients with chronic GVHD and steroid-refractory GVHD.

An expert in hematology/oncology, Dr Yi-Bin Chen, provides insight on chronic GvHD, with a focus on early detection of disease and therapeutic options for the management of steroid-refractory chronic GvHD.